IGY-110 (IGY Life Sciences)

N/A

Report date: 2025/01/26 18:42:12

Base Information

Drug NameIGY-110 (IGY Life Sciences)
Drug Alias Nameanti-CoV-2 therapeutic polyclonal IGY antibody (IGY Life Sciences)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Polyclonal antibodies
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIGY Life Sciences USA Inc
China Registration ClassN/A

Develop Information

Active CompaniesIGY Life Sciences USA Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A